FCF Fox Corporate Finance | FCF Life Sciences Life Sciences Monitor – Europe

February 2021 Antibody Agenda

FCF LIFE SCIENCES OVERVIEW FCF Life Sciences Overview

Overview Services Facts and Figures

Focus on Biotech, MedTech and HealthTech Collaboration Over Over Life Sciences with Management Team of 100 years EUR 2bn We advise innovative companies on arranging, structuring and placing equity BioScience Presentation 10 in aggregated Life Sciences and transactions in a holistic financing approach. Valuation and Life Sciences transaction based in Munich Integrated YAFO Capital experience volume1 Financial Modeling Focus Areas Over Post- Access to 7 Transaction 80 Leading > 1500 regularly FCF advises with its dedicated Life Sciences team on the following Support completed Life published Life international EIB advisor transaction types: Sciences Sciences Investor investors in Europe Screening transactions1 reports

1 including Professionals and Life Sciences Advisors Investor / IB Venture China Roadshow Equity Life Sciences Research Series Debt Licensing Due Diligence Support Life Sciences Venture Biotech Venture Capital Monitor – US Equity & Debt Capital Monitor – Europe Life Sciences Team Fundraising

Financing Strategy Advisory Life Sciences Venture Biotech Licensing Capital Report Monitor – China Closing Assistance Prof. Dr. Arno Fuchs Dr. Alexandra Dr. Joachim Alexander Kuhn Horst Domdey CEO Goll M. Greuel Analyst Life Sciences Life Sciences Life Sciences Term Sheet Advisor Advisor Advisor Negotiation Biotech Public Equity MedTech Public Equity IPO Monitor Monitor Execution Support Life Science Advisory Life Sciences IPO Dr. Axel Polack Claus Schalper Dr. Mathias Enno Spillner Sebastian (extract from service Board Report Life Sciences Life Sciences Schott Life Sciences Sommer portfolio) Advisor Advisor Director Advisor Associate

3 Executive Summary

The FCF Life FCF Life Sciences Venture Capital Monitor - Europe Recipients Sciences Venture Capital Monitor - is a monthly published overview of Biotech, Pharmaceutical, The FCF Life Sciences Venture Capital Monitor - Europe targets the Europe is a monthly MedTech and HealthTech companies, displaying venture capital following recipients: published overview financing trends in the European life science industry ▪ Corporates / Executives ▪ Venture capital investors focusing on the ▪ Institutional investors ▪ Family Offices / High- venture capital ▪ investors net-worth individuals financing ▪ Advisors environment in the Scope Biotech, Pharmaceutical, The selection of companies is based on the following criteria: Availability MedTech and HealthTech ▪ Focus on transactions with European headquartered life science The FCF Life Sciences Venture Capital Monitor - Europe is available segments, and can companies and available deal volume on FCF’s website at “https://www.fcf.de/de/life-sciences/” be used as a quick ▪ Companies operating in the Biotech, Pharmaceutical, MedTech, reference for HealthTech, Services or other life science related sectors Data investors, corporates and professionals ▪ The Biotech sector is further divided into the following therapy All input data is provided by Pitchbook or GlobalData and is not areas / indications: Cardiovascular, Central Nervous System, independently verified by FCF. Ratio and multiple calculations are Dermatology, Ear Nose Throat Disorders, Gastrointestinal, driven based on the input data available. For additional information Genetic Disorders, Genito Urinary System And Sex Hormones, and disclaimer, please refer to the last page More advanced, Hematological Disorders, Hormonal Disorders, Immunology, detailed and / or Infectious Disease, Male Health, Metabolic Disorders, Mouth and Dental Disorders, Musculoskeletal, Non Malignant Disorders, customized reports Nutritional Disorders, Oncology, Ophthalmology, Respiratory, are available upon Toxicology, Women's Health request

To recommend colleagues or fellow investors to be added to the If you have questions, comments or ideas, please do not hesitate mailing list, kindly send an email with the respective contact to contact us information

4 Agenda

EUROPEAN VENTURE CAPITAL TRANSACTIONS IN LIFE SCIENCES

FEBRUARY 2021 European Venture Capital Transactions in Life Sciences February 2021

Deal Total Vertical - Indication / Volume Raised Overview (YTD) # Date Company HQ Subsector Stage Company Description Series (EURm) (EURm) Deal Synopsis

Cumulative Financing Volume (EURm) Provider of a healthcare platform Nerve Stimulation 10,000 intended to use bioelectronic The company raised GBP 991,881 of angel funding on December 31, 2020, putting the 1 28-02-21 NuroKor GBR MedTech Devices / - 1 2 technology to work in natural company's pre-money valuation at GBP 12.97 million. 8,000 On market harmony with the body system. 6,000

4,000 The company raised EUR 1.5 million of venture funding on February 26, 2021. The company will use the funding to conduct a health economic trial and complete the 1,333 Developer of a digital healthcare 2,000 approval process of the Kata app by the German Federal Institute for Drugs and 2021 Respiratory Diseases / assistant application designed to 2020 2 26-02-21 VisionHealth DEU HealthTech C 2 3 Medical Devices, BfArM, as a digital health application within the framework of the On market control respiratory diseases in 0 German Digital Health Care Act (DVG), which will enable permanent reimbursement everyday life. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec by german health companies, to enter the market in Germany and generate Financing Volume (February 2021): EUR 403m revenue, via licensing Kata to pharmaceutical and medtech companies. Subsectors Indications1 Healthcare Medical Device for Developer of a medical device Services The company raised EUR1.0625 million of equity on February 26, 2021 3 26-02-21 VB Devices ESP MedTech Varicose Veins / designed to treat varicose veins - 1 1 Others putting the pre-money valuation at EUR 5.5 million. HealthTech On market with sclerotherapy. 4% Genetic 13% 10% Disorders 7% Oncology Immunology 38% MedTech EUR EUR 19% 9% 1,333m 889m Developer of a genetic inference 67% 11% Genomic Sequence Data technology designed to lead the The company raised $30 million of venture funding on February 25, 2021. The funds Biotech / Central 4 25-02-21 Genomics GBR HealthTech Analysis / genomic transformation by finding C 25 76 will be used to expand its work building a patient-centric, population health platform Pharma Nervous 22% System On market new drug targets for serious that unlocks a more proactive, precise and personalised form of healthcare. diseases. Metabolic Disorders

Top Company Origins Top Investor Origins Developer of DO-2 program The company raised EUR 999,996 of venture funding on February 24, 2021, putting Biotech / Oncology / 5 24-02-21 DeuterOncology BEL intended to provide oncology A 1 1 the company's pre-money valuation at EUR 399,750. The fund will be used to advance Others Pharma Phase II services for clinicians and patients. the development of our lead program DO-2 towards Phase I clinical trials. Others 14% 25% 10% 35% 36% EUR EUR

11% 1,333m 6% 1,333m Developer of diagnostic technology The company raised GBP 800,000 of venture funding on February 24, 2021. The funds 7% Diagnostics / intended to facilitate molecular 6 24-02-21 Linear Diagnostics GBR MedTech D < 1 7 will be used to facilitate the ongoing development of the company's high-speed 12% 18% 14% On market diagnostics tests using a simple 12% platform technology for point-of-care diagnostics. optical system.

Top 5 Deals Top 5 Investors Deal Deal # of # Company HQ Volume Series # Investor HQ Volume2 Deals Biotech / Other / Developer of drugs intended for The company raised PLN 4 million of angel funding on February 24, 2021. The funds 7 24-02-21 Bioceltix POL - < 1 2 NewAmsterdam Pharma Discovery veterinary therapy and treatments. will be used to fund research and further development of drug candidates. 1 160 A 1 BlackRock 144 1 Pharma Zukunftsfonds 2 Immunocore 144 C 2 60 1 Heilbronn

3 IO Biotech 127 B 3 OrbiMed 26 1 The company raised GBP 5.25 million of venture funding on February 23, 2021, putting Developer of a biotechnology Biotech / Other / the company's pre-money valuation at GBP 7.01 million. The funds will be used to Redmile 8 23-02-21 Newcells Biotech GBR platform designed to produce C 6 15 4 eCential Robotics 100 C 4 26 1 Pharma On market spearhead its international expansion in the USA, growing its existing commercial Group induced pluripotent stem cells. operations and launching innovative new products. Evox The Invus 5 79 C 5 26 1 Therapeutics Group

Source: PitchBook as of 22.03.2021; FCF Equity Research; GlobalData Note: All volumes in EURm; financing rounds without deal values are excluded 6 1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round) European Venture Capital Transactions in Life Sciences February 2021

Deal Total Vertical - Indication / Volume Raised Overview (YTD) # Date Company HQ Subsector Stage Company Description Series (EURm) (EURm) Deal Synopsis

Cumulative Financing Volume (EURm) Volatile Anesthetic Developer of a technology system 10,000 SageTech Medical The company raised GBP 3.07 million of venture funding on February 23, 2021, putting 9 23-02-21 GBR MedTech Gases / intended to extract and purify A 4 5 Equipment the company's pre-money valuation at GBP 6.41 million. 8,000 On market volatile anesthetic gases.

6,000

4,000 1,333 2,000 Manufacturer of plug-and-play 2021 Sports Prosthetics / 2020 10 23-02-21 Levitate DNK MedTech exercise and sports prosthetics A < 1 < 1 The company raised DKK 5.5 million of venture funding on February 23, 2021. On market 0 intended to empower amputees. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Financing Volume (February 2021): EUR 403m Subsectors Indications1 Provider of a digital health platform Healthcare Online Mental Health The company raised GBP 500,000 of angel funding on February 21, 2021. The Services Healthcare intended to utilizes the lived or 11 21-02-21 Frog Systems GBR Coaching / - < 1 < 1 company will use the fund to make a real difference to society at a time when mental Others Services shared experience to deliver help HealthTech On market health and wellbeing are top of most people's agenda. and support. 4% Genetic 13% 10% Disorders 7% Oncology Immunology 38% MedTech EUR EUR 19% 9% 1,333m 889m Developer of a biotechnology 67% 11% device intended to prevent brain Biotech / Oxford Blood Flow Diverter / The company raised GBP 6.47 million of Series 2 venture funding on February 19, Central 12 19-02-21 GBR MedTech hemorrhage by treating brain 2 7 14 Pharma Nervous 22% Endovascular Pre-clinic 2021, putting the company's pre-money valuation at GBP 15.00 million. System aneurysms, a condition that affects 1 in 50 persons. Metabolic Disorders

Developer of exosome-based Top Company Origins Top Investor Origins therapeutics designed to treat The company raised $95.4 million of Series C venture funding on February 18, 2021. Biotech / Central Nervous System / 13 18-02-21 Evox Therapeutics GBR various severe diseases with C 79 131 The funds will be used to expand into new diseases and modalities, including Others Pharma Pre-clinic profound implications for human delivering gene therapy and gene editing. Others health. 14% 25% 10% 35% 36% EUR EUR

11% 1,333m 6% 1,333m AI-based Real-World Developer of an AI-based real- The company raised EUR 6.3 million of Series A venture funding on February 18, 7% Evidence Generation world evidence generation tool built 14 18-02-21 Semalytix DEU HealthTech A 6 6 2021. The funds will be used to expand the software, improve performance and further 12% 18% 14% Tool / to ingest and process forum and 12% strengthen the market position. On market social media data.

Top 5 Deals Top 5 Investors The company raised EUR 5.75 million of Series A venture funding on February 17, Deal Deal # of 2 Developer of robotic technologies 2021, putting the company's pre-money valuation at an estimated EUR 39.93 million. # Company HQ Volume Series # Investor HQ Volume Deals Retinal Microsurgery / 15 17-02-21 AcuSurgical FRA MedTech and tools designed for retinal A 6 6 The funds will be used to conduct clinical trials and reach regulatory approval with NewAmsterdam Developing 1 160 A 1 BlackRock 144 1 microsurgery. vitreo-retinal surgery as the first indication, paving the way for future applications that Pharma are not within the reach of surgeons today. Zukunftsfonds 2 Immunocore 144 C 2 60 1 Heilbronn

3 IO Biotech 127 B 3 OrbiMed 26 1 Developer of remote monitoring Rremote Monitoring device designed to offer The company raised GBP 75,005 of Series 1 venture funding on February 17, 2021, Redmile 16 17-02-21 GripAble GBR MedTech Device / 1 < 1 2 4 eCential Robotics 100 C 4 26 1 assessment and training of hand putting the company's pre-money valuation at GBP 8.73 million. Group On market functions. Evox The Invus 5 79 C 5 26 1 Therapeutics Group

Source: PitchBook as of 22.03.2021; FCF Equity Research; GlobalData Note: All volumes in EURm; financing rounds without deal values are excluded 7 1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round) European Venture Capital Transactions in Life Sciences February 2021

Deal Total Vertical - Indication / Volume Raised Overview (YTD) # Date Company HQ Subsector Stage Company Description Series (EURm) (EURm) Deal Synopsis

Cumulative Financing Volume (EURm) Developer of medical devices Nerve Stimulation against The company raised EUR 2 million of venture funding on February 16, 2021. The 10,000 Atlantic intended to offer pelvic floor muscle 17 16-02-21 IRL MedTech Incontinence / D 2 30 funds will be used to support the company's route to commercialising the treatment in Therapeutics strengthening and nerve stimulation 8,000 On market the US and UK markets. products. 6,000

4,000

2,000 1,333 Developer of vaccines designed to 2021 Biotech / Infectious Diseases / offer actionable innovation and The company raised EUR 20.46 million of venture funding on February 15, 2021, 2020 18 15-02-21 Theravectys FRA E 20 52 0 Pharma Phase II bring a spectacular paradigm shift putting the company's pre-money valuation at EUR 143.31 million. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec into vaccinology. Financing Volume (February 2021): EUR 403m Subsectors Indications1 Developer of a medical device Healthcare Cardiac Micrograft Services created to enable surgical 19 15-02-21 EpiHeart FIN MedTech Therapy / - < 1 < 1 The company raised EUR 608,399 of equity crowdfunding on February 15, 2021. Others administration of novel cellular and HealthTech Developing gene therapies. 4% Genetic 13% 10% Disorders 7% Oncology Immunology 38% MedTech EUR EUR 19% 9% 1,333m 889m Developer of genome informatics 67% 11% Biotech / Genome Informatics / intended to provide development in The company raised PLN 700,000 of venture funding on February 15, 2021, putting Central 20 15-02-21 Intelliseq POL HealthTech B < 1 < 1 Pharma Nervous 22% On market pharmacogenomics and the company's pre-money valuation at PLN 9.87 million. System transcriptomics.

Metabolic Disorders

Top Company Origins Top Investor Origins Developer of T regulatory (Treg) Biotech / Immunology / 21 12-02-21 QuellTX GBR cells designed to treat diseases of A 70 70 The company raised $84.5 million of Series A venture funding on February 12, 2021. Others Pharma Pre-clinic the immune system. Others 14% 25% 10% 35% 36% EUR EUR

11% 1,333m 6% 1,333m Operator of a therapeutic company 7% Neuropain Biotech / Central Nervous System / 22 12-02-21 FRA intended to develop neuropathic - 3 3 The company raised EUR 2.5 million of angel funding on February 12, 2021. 12% 18% 14% Therapeutics Pharma Pre-clinic 12% and inflammatory pain drugs.

Top 5 Deals Top 5 Investors Deal Deal # of Provider of digital therapeutic 2 Digital Therapeutic # Company HQ Volume Series # Investor HQ Volume Deals Healthcare services intended for personalized 23 12-02-21 Quin GBR Services / - 1 3 The company raised GBP 914,772 of angel funding on February 12, 2021. NewAmsterdam Services independent self-management of 1 160 A 1 BlackRock 144 1 On market Pharma type 1 diabetes. Zukunftsfonds 2 Immunocore 144 C 2 60 1 Heilbronn

3 IO Biotech 127 B 3 OrbiMed 26 1 Developer of cell-free synthetic Cell-free Synthetic Biology The company raised EUR 11 million of Series A venture funding on February 11, 2021. Healthcare biology platform intended to provide Redmile 24 11-02-21 EnginZyme SWE Platform / A 11 15 This funding round will allow the company to demonstrate that the problem is solvable, 4 eCential Robotics 100 C 4 26 1 Services an alternative for various types of Group On market and that the approach is a versatile and scalable solution. plastics. Evox The Invus 5 79 C 5 26 1 Therapeutics Group

Source: PitchBook as of 22.03.2021; FCF Equity Research; GlobalData Note: All volumes in EURm; financing rounds without deal values are excluded 8 1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round) European Venture Capital Transactions in Life Sciences February 2021

Deal Total Vertical - Indication / Volume Raised Overview (YTD) # Date Company HQ Subsector Stage Company Description Series (EURm) (EURm) Deal Synopsis

Cumulative Financing Volume (EURm) Operator of a biotechnology The company raised $32.5 million of Series A venture funding on February 10, 2021. 10,000 Biotech / Infectious Diseases / platform intended to generate next- 25 10-02-21 SpyBiotech GBR A 27 46 The funds will be used to support its novel vaccine platform through accelerated Pharma Phase II generation vaccines against 8,000 clinical development. bacterial infections. 6,000

4,000 1,333 Provider of a therapeutic based 2,000 Trained 2021 Biotech / Immunology / platform intended to employ 2020 26 10-02-21 Therapeutics DEU - 5 5 The company raised $ 6,012,067 of angel funding on February 10, 2021. Pharma Pre-clinic bioengineering methods to produce 0 Discovery Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec nanobiologic therapeutics. Financing Volume (February 2021): EUR 403m Subsectors Indications1 Healthcare Medical Technology to Developer of medical technology The company raised EUR 1.2 million of venture funding on February 10, 2021. The Services Others 27 10-02-21 Maculaser FIN MedTech Prevent Blindness / intended to prevent blindness by A 1 1 fund will be used to accelerate product commercialization and move the company to HealthTech On market targeting major retinal diseases. the clinical trial phase. 4% Genetic 13% 10% Disorders 7% Oncology Immunology 38% MedTech EUR EUR 19% 9% 1,333m 889m The company raised EUR 30 million of Series A venture funding on February 9, 2021. 67% 11% Streamlined Dashboard Developer digital healthcare The funds will be used for product development, including expanding the diagnoses Biotech / Central 28 09-02-21 Koa Health NLD HealthTech for Clinicians / solutions designed to offer stepped A 30 30 that the company's solutions can support, adding more wellness content, making Pharma Nervous 22% System On market care for mental health. programs available in new languages and to break into international markets, including North America. Metabolic Disorders

The company raised EUR 18.5 million of Series B venture funding on February 9, Top Company Origins Top Investor Origins 2021. The funds will be used for the clinical evaluation of the Company's microRNA InteRNA Biotech / Oncology / Developer of RNA therapeutics 29 09-02-21 NLD B 19 29 lead candidate, INT-1B3, in patients with advanced solid tumors and to develop and Others Technologies Pharma Phase I intended for cancer treatment. advance additional proprietary preclinical drug candidates addressing a variety of Others cancer indications. 14% 25% 10% 35% 36% EUR EUR

11% 1,333m 6% 1,333m Provider of health tracking platform 7% Health Tracking Platform / The company raised EUR 650,000 of angel funding on February 8, 2021. The fund will 30 08-02-21 PacSana IRL MedTech intended to promote technology - < 1 < 1 12% 18% 14% On market be used by the company to grow its business in the United States. 12% enabled care.

Top 5 Deals Top 5 Investors Deal Deal # of Developer of advanced nanowire- 2 Nanowire-based The company raised SEK 23 million of Series A venture funding on February 6, 2021. # Company HQ Volume Series # Investor HQ Volume Deals based biosensor system designed 31 06-02-21 Aligned Bio SWE MedTech Biosensor System / A 2 3 The company intends to use the funds to ramp production of its first product and NewAmsterdam for the biosensor and electronics 1 160 A 1 BlackRock 144 1 On market conclude the development phase of its sequencer product. Pharma industries. Zukunftsfonds 2 Immunocore 144 C 2 60 1 Heilbronn

3 IO Biotech 127 B 3 OrbiMed 26 1 Developer of an online platform The company raised EUR 310,000 of angel funding on February 6, 2021. The Redmile Healthcare Online Platform / intended to connect family fundraising will allow the company to accelerate the technological development of its 4 eCential Robotics 100 C 4 26 1 32 06-02-21 Ernesti FRA - < 1 < 1 Group Services On market caregivers looking for a night platform, and to develop their presence at the national level and in particular in rural presence for their loved ones. areas. Evox The Invus 5 79 C 5 26 1 Therapeutics Group

Source: PitchBook as of 22.03.2021; FCF Equity Research; GlobalData Note: All volumes in EURm; financing rounds without deal values are excluded 9 1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round) European Venture Capital Transactions in Life Sciences February 2021

Deal Total Vertical - Indication / Volume Raised Overview (YTD) # Date Company HQ Subsector Stage Company Description Series (EURm) (EURm) Deal Synopsis

Cumulative Financing Volume (EURm) The company raised EUR 22.6 million of venture funding on February 5, 2021. The Developer of RNA-based immuno- 10,000 Highlight Biotech / Oncology / funds will be used to validate the therapeutic use of its compound in combination with 33 05-02-21 ESP oncology therapies intended to D 23 34 Therapeutics Pharma Phase II agents approved but that currently have very limited efficacy in various solid tumors 8,000 combat cancer. such as melanoma, and gastric and colorectal cancers. 6,000

4,000 1,333 Developer of an online consultation 2,000 Online Consultation The company raised GBP 7 million of venture funding on February 5, 2021. The funds 2021 Healthcare platform intended to enhance 2020 34 05-02-21 eConsult GBR Platform / B 8 14 will be used for the rollout of the Company's Urgent and Emergency Care tool, Services patient access and improve 0 On market eTriage, and outpatient triage tool, eSpecialist. Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec practice efficiencies. Financing Volume (February 2021): EUR 403m Subsectors Indications1 Developer of a liquid biopsy The company raised $35 million of Series C venture funding on February 4, 2021. The Healthcare Cancer Genomics platform designed to unlock Services funds will be used to accelerate the clinical development and continued rollout of 35 04-02-21 Inivata GBR MedTech Monitoring Platform / essential genomic information from C 29 144 Others RaDaR™, the UK company's highly sensitive personalised assay for the detection and HealthTech On market a simple blood draw to guide and monitoring of minimal residual disease (MRD) and recurrence. 4% Genetic 13% personalize cancer treatment. 10% Disorders 7% Oncology Immunology 38% MedTech EUR EUR 19% 9% 1,333m 889m 67% 11% Application for Cardiac Developer of a medical application Biotech / The company raised EUR 9 million of venture funding on February 3, 2021. The Central 36 03-02-21 FibriCheck BEL HealthTech Arrhythmia / designed to detect cardiac B 9 11 Pharma Nervous 22% funding will be used to further accelerate the growth of the company's business units. System On market arrhythmia via a smartphone.

Metabolic Disorders

Developer of a MedTech platform Top Company Origins Top Investor Origins The company raised EUR 1.5 million of equity crowdfunding on February 2, 2021, Telemedicine Tool / intended to solve systemic 37 02-02-21 Akkure IRL HealthTech - 2 1 putting the company's pre-money valuation at EUR 4 million. The funds will be used to Others Developing problems in the clinical trials support an expansion of its clinical trials platform. industry. Others 14% 25% 10% 35% 36% EUR EUR

11% 1,333m 6% 1,333m Developer of monitoring sensors 7% Bladder Diagnostics / The company raised $100,000 of venture funding in the form of SAFE notes on 38 01-02-21 Invivo Bionics NOR MedTech intended to revolutionize bladder A < 1 < 1 12% 18% 14% Developing February 1, 2021. 12% diagnostics.

Top 5 Deals Top 5 Investors Deal Deal # of # Company HQ Volume Series # Investor HQ Volume2 Deals NewAmsterdam 1 160 A 1 BlackRock 144 1 Pharma Zukunftsfonds 2 Immunocore 144 C 2 60 1 Heilbronn

3 IO Biotech 127 B 3 OrbiMed 26 1

Redmile 4 eCential Robotics 100 C 4 26 1 Group Evox The Invus 5 79 C 5 26 1 Therapeutics Group

Source: PitchBook as of 22.03.2021; FCF Equity Research; GlobalData Note: All volumes in EURm; financing rounds without deal values are excluded 10 1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round) Contact Details & Disclaimer

DISCLAIMER

This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or may be relied upon in connection with any contract or commitment whatsoever. No representation or warranty (express or FCF Fox Corporate Finance GmbH implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany liability whatsoever is accepted as to any errors, omissions or misstatements Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299 contained herein, and, accordingly, neither FCF nor any of its officers, directors [email protected] ▪ www.fcf.de or employees accepts any liability whatsoever arising directly or indirectly from the use of this document. By accepting this document you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future Arno Fuchs Dr. Mathias Schott performance of the Company's business. This document contains certain Chief Executive Officer Director forward-looking statements, including assumptions, opinions and views cited P: +49 (89) 206 0409-100 P: +49 (89) 206 0409-123 from third party sources. Various known and unknown risks, uncertainties and M: +49 (172) 863 6777 M: +49 (174) 301 1846 other factors could cause the actual results, financial position, development or [email protected] [email protected] performance of the Company to differ materially from the estimations expressed or implied herein. FCF does not guarantee that the figures, assumptions and calculations underlying such historical and forward looking Sebastian Sommer Alexander Kuhn statements are free from errors nor does FCF accept any responsibility for the Associate Analyst future accuracy of the opinions expressed in this document or the actual P: +49 (89) 206 0409-130 P: +49 (89) 206 0409-120 occurrence of the forecasted developments. M: +49 (172) 839 5738 M: +49 (173) 590 6671 [email protected] [email protected] © FCF Fox Corporate Finance GmbH 2021

11